SCHEMBL4601464

SCHEMBL4601464

COc1cc(-c2cc(C(=O)N[C@H](CO)Cc3c[nH]c4ccccc34)c3ccccc3n2)cc(OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
POLB P06746 3/20 0.54
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
KDM4E B2RXH2 7/20 0.53
ALDH1A1 P00352 4/20 0.53
LMNA P02545 2/20 0.53
HPGD P15428 1/20 0.53
ATM Q13315 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
UBE2I P63279 1/20 0.49
SAE1 Q9UBE0 1/20 0.49
UBA2 Q9UBT2 1/20 0.49
RAB9A P51151 1/20 0.49
ROCK2 O75116 1/20 0.48
ROCK1 Q13464 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TACR3 P29371 1/20 0.48
HTT P42858 1/20 0.47
DHODH Q02127 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4601818 1.00 MAPT (0.54) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL4601369 0.93 MAPT (0.51) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL4601374 0.93 MAPT (0.51) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL5155685 0.93 MAPT (0.51) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL4601433 0.93 MAPT (0.51) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL4601366 0.93 MAPT (0.51) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL5155674 0.93 MAPT (0.51) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL4601429 0.93 MAPT (0.51) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL4601437 0.93 MAPT (0.51) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL5155672 0.93 MAPT (0.51) MAPTPOLBMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US claimed
EP-1912970-A2 ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-23 EP disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed
WO-2007017289-A2 ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-02-15 WO disclosed
WO-2007017289-A2 ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R MAPT 4047/4885POLB 4403/4885MEN1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.